Regarding continuation or discontinuation of treatment, the hazard ratio of SGLT2 inhibitors on stroke was steady36, and it is currently difficult to prove that patient withdrawal from randomized treatment has any adverse effect on the risk of stroke. This evidence concerns the gene SLC5A2 and stroke disorder.